Generic drug
Raloxifene price, strengths & recalls
Generic of Evista
Pharmacies pay $6.62 for 30 tablets of Raloxifene 60 mg tablet this week. 16 manufacturers make it. It has 2 recalls on record, none ongoing. Its official label last changed on April 29, 2026.
Generic- Fair cash price
- $18.11
- Strengths
- 1
- Makers
- 16
- Updated
- Nov 11
Raloxifene price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 60 mg tablet | $0.2205 | $6.62 / 30 tablets |
Brand names of raloxifene
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Raloxifene
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use RALOXIFENE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for RALOXIFENE HYDROCHLORIDE TABLETS.RALOXIFENE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1997
WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE
Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene hydrochloride [see Warnings and Precautions (5.1)]. Women with active or past history of venous thromboembolism should not take raloxifene hydrochloride [see Contraindications (4.1)].
Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke [see Warnings and Precautions (5.2) and Clinical Studies (14.5)].
WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE
See full prescribing information for complete boxed warning.
Increased risk of deep vein thrombosis and pulmonary embolism has been reported with raloxifene hydrochloride (5.1). Women with active or past history of venous thromboembolism should not take raloxifene hydrochloride (4.1).
Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke (5.2, 14.5).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA020815 · Lilly
- First approved
- December 9, 1997 (29 years ago)
- Latest approved change
- June 27, 2018
- Approved label
- PDF, Jul 5, 2018
- Generic makers
- 6 approved generic applications on the market
Raloxifene questions
How much does raloxifene cost without insurance?
Pharmacies pay about $6.62 for 30 tablets of raloxifene 60 mg tablet ($0.2205 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $18.11. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of raloxifene?
Raloxifene is sold as Evista. The generic has the same active ingredient and usually costs far less.
Is raloxifene in shortage?
No shortage is reported for raloxifene right now. We check the national shortage list every day.
Has raloxifene been recalled?
2 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the raloxifene label last change?
The official label was last updated on April 29, 2026 (version 16). See what changed.
Talk about raloxifene
No comments yet. Questions, tips, what worked for you - start the conversation.